Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 -...
Autism
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Little Leaves Behavioral Services Opens New Location in Lutherville, Maryland
ABA therapy center meets growing need for high-quality, early intervention resources for young children with autismLUTHERVILLE, Md., Sept. 29, 2022...
PaxMedica, Inc. Provides Corporate Update After IPO
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer- -Second Independent Director, Dr. John...
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes
TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace TEL AVIV, Israel, Sept....
Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of...
PaxMedica, Inc. Announces Pricing of Initial Public Offering
Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD” TARRYTOWN, NY, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via...
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022...
Scisparc Announces the Full Exercise of Pre-Funded Warrants
The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug....
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel,...
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD...
Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for...
ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022
Oryzon invests $8.1 million in R&D in the first half 2022MADRID, Spain and BOSTON, July 22, 2022 (GLOBE NEWSWIRE) --...
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)
CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation...
Children’s Cancer Foundation receives $100,000 in donations in 4 hours as a result of Sports Card Company Backyard Breaks
The Florida-Based Sports Card Company that's changing lives one stream at a time BOCA RATON, Fla., July 14, 2022 /PRNewswire/...
Sparkt Bridges: Young Man and His Art Have Deeper Message
By Anne Linaberger Jarrod Edson's talent is astounding. It's helping him make a difference, and demonstrating that his disability is...